Compare SGRY & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | HROW |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2015 | 2008 |
| Metric | SGRY | HROW |
|---|---|---|
| Price | $14.19 | $40.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $22.25 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 2.2M | 539.0K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.14 | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,145,438,000.00 | N/A |
| Revenue This Year | $5.09 | $31.62 |
| Revenue Next Year | $5.67 | $50.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.41 | $28.54 |
| 52 Week High | $23.66 | $54.98 |
| Indicator | SGRY | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 53.97 |
| Support Level | $13.45 | $40.65 |
| Resistance Level | $15.24 | $42.11 |
| Average True Range (ATR) | 0.84 | 1.96 |
| MACD | -0.17 | 0.26 |
| Stochastic Oscillator | 20.67 | 68.13 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.